Bio Historical Financial Ratios
| BPTH Stock | USD 0.77 0.03 3.75% |
Bio Path is presently reporting on over 106 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 10.54 or Days Sales Outstanding of 56.42 will help investors to properly organize and evaluate Bio Path Holdings financial condition quickly.
Bio |
About Bio Financial Ratios Analysis
Bio Path HoldingsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Bio Path investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Bio financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Bio Path history.
Bio Path Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Bio Path Holdings stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Bio Path sales, a figure that is much harder to manipulate than other Bio Path Holdings multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Bio Path's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Bio Path Holdings current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. As of now, Bio Path's Average Inventory is decreasing as compared to previous years. The Bio Path's current Capex To Revenue is estimated to increase to 13.74, while Price To Sales Ratio is projected to decrease to 471.68.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 1.52 | 0.27 | 0.39 | 0.37 | Days Of Inventory On Hand | 1.19 | 7.36 | 8.46 | 8.04 |
Bio Path fundamentals Correlations
Click cells to compare fundamentals
Bio Path Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Path fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 1.01 | 0.89 | 1.0 | 0.78 | 10.04 | 10.54 | |
| Book Value Per Share | 158.72 | 78.35 | 75.71 | 38.96 | 0.92 | 0.88 | |
| Free Cash Flow Yield | (2.94) | (0.39) | (0.81) | (1.38) | (2.61) | (2.48) | |
| Operating Cash Flow Per Share | (62.94) | (56.98) | (29.49) | (41.51) | (24.13) | (25.34) | |
| Capex To Depreciation | 1.31 | 0.0399 | 0.43 | 0.12 | 0.11 | 0.1 | |
| Pb Ratio | 1.01 | 0.89 | 1.0 | 0.78 | 10.04 | 10.54 | |
| Free Cash Flow Per Share | (62.94) | (56.98) | (29.7) | (41.57) | (24.13) | (25.34) | |
| Roic | (6.55) | (0.41) | (0.72) | (0.97) | (29.12) | (27.67) | |
| Net Income Per Share | (64.02) | (56.44) | (31.04) | (38.03) | (33.64) | (35.32) | |
| Payables Turnover | 0.47 | 1.51 | 1.52 | 0.27 | 0.39 | 0.37 | |
| Cash Per Share | 153.75 | 71.51 | 70.7 | 28.54 | 2.2 | 2.09 | |
| Pocfratio | (2.54) | (1.23) | (2.56) | (0.73) | (0.38) | (0.4) | |
| Capex To Operating Cash Flow | (0.0676) | (0.002776) | (0.007059) | (0.00139) | (0.001251) | (0.001314) | |
| Pfcf Ratio | (0.34) | (2.54) | (1.23) | (0.73) | (0.38) | (0.4) | |
| Days Payables Outstanding | 771.26 | 241.72 | 240.31 | 1.4K | 937.11 | 983.96 | |
| Income Quality | 0.97 | 1.01 | 0.95 | 1.09 | 0.72 | 0.66 | |
| Roe | (0.4) | (0.72) | (0.41) | (0.98) | (36.46) | (34.64) | |
| Ev To Operating Cash Flow | (0.18) | (0.15) | (0.003604) | (0.0545) | (0.3) | (0.32) | |
| Pe Ratio | (2.5) | (1.24) | (2.43) | (0.79) | (0.28) | (0.29) | |
| Return On Tangible Assets | (3.68) | (0.38) | (0.66) | (0.39) | (4.99) | (4.74) | |
| Ev To Free Cash Flow | (0.18) | (0.15) | (0.003604) | (0.0545) | (0.3) | (0.32) | |
| Earnings Yield | (0.4) | (0.81) | (0.41) | (1.26) | (3.63) | (3.45) | |
| Net Debt To E B I T D A | 2.39 | 1.25 | 2.29 | 0.74 | 0.0596 | 0.0566 | |
| Current Ratio | 17.68 | 13.65 | 27.29 | 9.27 | 1.6 | 1.52 | |
| Tangible Book Value Per Share | 158.72 | 78.35 | 75.71 | 38.96 | 0.92 | 0.88 | |
| Graham Number | 478.15 | 315.42 | 229.94 | 182.58 | 26.42 | 25.1 | |
| Shareholders Equity Per Share | 158.72 | 78.35 | 75.71 | 38.96 | 0.92 | 0.88 | |
| Capex Per Share | 21.35 | 0.57 | 0.21 | 0.0577 | 0.0664 | 0.0631 |
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.